Product news

Share this article:
The FDA warned healthcare professionals about six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta (exenatide), indicated for Type 2 diabetes. Amylin and Eli Lilly & Co., joint manufacturers of Byetta, will make labeling changes featuring more prominent warnings about the risk of acute hemorrhagic or necrotizing pancreatitis.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions